Amylyx Pharmaceuticals (AMLX) Earnings Date & Reports

Key Takeaways

• Amylyx reported a net loss of $45.5 million, or $0.38 per share, for the third quarter of 2026, roughly in line with the consensus estimate of a $0.38 loss per share.
• The company's cash and cash equivalents jumped to $768 million, up from $251 million at the end of the second quarter, after a $545 million oversubscribed equity offering.
• Total operating expenses rose 38% year over year to $49.7 million, driven by spending on the pivotal LUCIDITY trial and pre-commercialization activities.
• Management is advancing avexitide, its lead drug candidate for post-bariatric hypoglycemia (PBH, a condition causing dangerously low blood sugar after weight-loss surgery), toward a potential launch in 2027.
• You can get more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover stocks and ETFs using AI-driven signals, explore our Trending AI Robots.

Earnings Context and Why It Matters

Amylyx Pharmaceuticals is a clinical-stage biotech that has shifted its focus to avexitide, a potential first approved treatment for PBH. This earnings report matters less for traditional revenue metrics and more for what it signals about the company's transition from clinical development to commercialization. Following positive results from the phase III LUCIDITY trial, Amylyx is now investing heavily in a launch-readiness roadmap while preparing a New Drug Application (NDA), a formal request for regulatory approval. For investors, the key questions center on cash runway, spending discipline, and execution toward a potential 2027 launch — all of which were in focus this quarter.

Reported Results

For the quarter ended September 30, 2026, Amylyx reported a net loss of $45.5 million, or $0.38 per share, compared with a net loss of $34.4 million, or $0.37 per share, in the same period a year earlier. The result was essentially in line with the Wall Street consensus estimate of a $0.38 loss per share.

Total operating expenses climbed 38% year over year to $49.7 million. Research and development (R&D) expenses rose to $28.4 million from $19.9 million, primarily reflecting spending tied to the LUCIDITY clinical trial and avexitide-related work, partially offset by reduced spending on AMX0035. Selling, general, and administrative (SG&A) expenses increased to $21.3 million from $16.2 million, driven by pre-commercialization hiring and related personnel costs. Non-cash stock-based compensation was $10.4 million, up from $7.1 million a year earlier.

The standout financial item was the balance sheet: Amylyx ended the quarter with $768 million in cash and cash equivalents, bolstered by $545 million in net proceeds from a recent equity offering. The company reported no product revenue during the period.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Whether you are tracking earnings movers like AMLX or scanning for new opportunities, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Heading into the report, investor attention was less on the headline loss and more on Amylyx's capital position and its path toward a potential 2027 launch of avexitide. The company's sharply expanded cash balance following its oversubscribed offering has been a central theme, giving management a stronger runway to fund launch preparation from a position of financial strength. In prior quarters, the stock had reacted sensitively to expense growth and EPS shortfalls, but the third-quarter results — including an in-line loss and a much larger cash cushion — reinforce a narrative of execution rather than deterioration. Sentiment remains tied to upcoming regulatory milestones and the broader PBH market opportunity rather than near-term profitability.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst for Amylyx is the progression of avexitide through the regulatory process. Management has indicated it is focused on NDA preparation, with the goal of potentially commercializing the first approved therapy for PBH in 2027. Amylyx estimates there are roughly 160,000 people living with PBH in the United States, a figure it says is supported by independent claims analysis.

Investors should also watch spending trends. The company is scaling its commercial organization across marketing, market access, patient services, and operations, which will continue to pressure operating expenses in coming quarters. How quickly Amylyx invests versus how it preserves its enlarged cash balance will be a key balance to monitor.

Beyond avexitide, the company is advancing AMX0318, a long-acting GLP-1 (glucagon-like peptide-1) receptor antagonist, in preclinical studies. While early stage, this program could broaden the pipeline over time. Upcoming investor events, including a presentation at ObesityWeek, may offer additional color on the PBH market and the avexitide data. As always, regulatory decisions and clinical updates — rather than quarterly losses — are likely to be the primary drivers of the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations